Bionime Corporation

Taiwan Stock Exchange 4737.TW

Bionime Corporation Total Non-Current Liabilities for the year ending December 31, 2023: USD 55.32 M

Bionime Corporation Total Non-Current Liabilities is USD 55.32 M for the year ending December 31, 2023, a 13.70% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Bionime Corporation Total Non-Current Liabilities for the year ending December 31, 2022 was USD 48.66 M, a 16.44% change year over year.
Bionime Corporation Total Non-Current Liabilities for the year ending December 31, 2021 was USD 41.79 M, a 0.18% change year over year.
Bionime Corporation Total Non-Current Liabilities for the year ending December 31, 2020 was USD 41.71 M, a 27.78% change year over year.
Bionime Corporation Total Non-Current Liabilities for the year ending December 31, 2019 was USD 32.64 M, a -10.46% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Taiwan Stock Exchange: 4737.TW

Bionime Corporation

CEO	Mr. Chun-Mu Huang
IPO Date	Dec. 23, 2010
Location	Taiwan
Headquarters	No. 100, Daqing Street
Employees	1,111
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Drugstores & Retail Pharmacies Hardware & Electronics Musical Instruments Personal Care Pharmaceuticals

Description

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

Key trends

Past 5 years